157 related articles for article (PubMed ID: 21619538)
1. TGF-β2 signaling in high-grade gliomas.
Hau P; Jachimczak P; Schlaier J; Bogdahn U
Curr Pharm Biotechnol; 2011 Dec; 12(12):2150-7. PubMed ID: 21619538
[TBL] [Abstract][Full Text] [Related]
2. Treatment of malignant gliomas with TGF-beta2 antisense oligonucleotides.
Hau P; Jachimczak P; Bogdahn U
Expert Rev Anticancer Ther; 2009 Nov; 9(11):1663-74. PubMed ID: 19895249
[TBL] [Abstract][Full Text] [Related]
3. The antisense oligonucleotide trabedersen (AP 12009) for the targeted inhibition of TGF-β2.
Jaschinski F; Rothhammer T; Jachimczak P; Seitz C; Schneider A; Schlingensiepen KH
Curr Pharm Biotechnol; 2011 Dec; 12(12):2203-13. PubMed ID: 21619536
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study.
Bogdahn U; Hau P; Stockhammer G; Venkataramana NK; Mahapatra AK; Suri A; Balasubramaniam A; Nair S; Oliushine V; Parfenov V; Poverennova I; Zaaroor M; Jachimczak P; Ludwig S; Schmaus S; Heinrichs H; Schlingensiepen KH;
Neuro Oncol; 2011 Jan; 13(1):132-42. PubMed ID: 20980335
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies.
Hau P; Jachimczak P; Schlingensiepen R; Schulmeyer F; Jauch T; Steinbrecher A; Brawanski A; Proescholdt M; Schlaier J; Buchroithner J; Pichler J; Wurm G; Mehdorn M; Strege R; Schuierer G; Villarrubia V; Fellner F; Jansen O; Straube T; Nohria V; Goldbrunner M; Kunst M; Schmaus S; Stauder G; Bogdahn U; Schlingensiepen KH
Oligonucleotides; 2007; 17(2):201-12. PubMed ID: 17638524
[TBL] [Abstract][Full Text] [Related]
6. Trabedersen, a TGFbeta2-specific antisense oligonucleotide for the treatment of malignant gliomas and other tumors overexpressing TGFbeta2.
Vallières L
IDrugs; 2009 Jul; 12(7):445-53. PubMed ID: 19579166
[TBL] [Abstract][Full Text] [Related]
7. Antisense therapeutics for tumor treatment: the TGF-beta2 inhibitor AP 12009 in clinical development against malignant tumors.
Schlingensiepen KH; Fischer-Blass B; Schmaus S; Ludwig S
Recent Results Cancer Res; 2008; 177():137-50. PubMed ID: 18084956
[TBL] [Abstract][Full Text] [Related]
8. Convection-enhanced delivery of a transforming growth factor-beta2 inhibitor trabedersen for recurrent high-grade gliomas: efficacy real or imagined?, in reference to Bogdahn et al. (Neuro-Oncology 2011;13:132-142).
Chamberlain MC
Neuro Oncol; 2011 May; 13(5):558-9; author reply 561-2. PubMed ID: 21558078
[No Abstract] [Full Text] [Related]
9. Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009.
Schlingensiepen KH; Schlingensiepen R; Steinbrecher A; Hau P; Bogdahn U; Fischer-Blass B; Jachimczak P
Cytokine Growth Factor Rev; 2006; 17(1-2):129-39. PubMed ID: 16377233
[TBL] [Abstract][Full Text] [Related]
10. Transforming growth factor-beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer.
Schlingensiepen KH; Jaschinski F; Lang SA; Moser C; Geissler EK; Schlitt HJ; Kielmanowicz M; Schneider A
Cancer Sci; 2011 Jun; 102(6):1193-200. PubMed ID: 21366804
[TBL] [Abstract][Full Text] [Related]
11. An imbalance between Smad and MAPK pathways is responsible for TGF-beta tumor promoting effects in high-grade gliomas.
Nickl-Jockschat T; Arslan F; Doerfelt A; Bogdahn U; Bosserhoff A; Hau P
Int J Oncol; 2007 Feb; 30(2):499-507. PubMed ID: 17203233
[TBL] [Abstract][Full Text] [Related]
12. Trabedersen to target transforming growth factor-beta: when the journey is not the reward, in reference to Bogdahn et al. (Neuro-Oncology 2011;13:132-142).
Wick W; Weller M
Neuro Oncol; 2011 May; 13(5):559-60; author reply 561-2. PubMed ID: 21558079
[No Abstract] [Full Text] [Related]
13. TGF-beta2 inhibition augments the effect of tumor vaccine and improves the survival of animals with pre-established brain tumors.
Liu Y; Wang Q; Kleinschmidt-DeMasters BK; Franzusoff A; Ng KY; Lillehei KO
J Neurooncol; 2007 Jan; 81(2):149-62. PubMed ID: 16941073
[TBL] [Abstract][Full Text] [Related]
14. TGF-β as a therapeutic target in high grade gliomas - promises and challenges.
Joseph JV; Balasubramaniyan V; Walenkamp A; Kruyt FA
Biochem Pharmacol; 2013 Feb; 85(4):478-85. PubMed ID: 23159669
[TBL] [Abstract][Full Text] [Related]
15. The influence of tamoxifen on the secretion of transforming growth factor-beta2 (TGF-beta2) in glioblastomas: in vitro and in vivo findings.
Puchner MJ; Köppen JA; Zapf S; Knabbe C; Westphal M
Anticancer Res; 2002; 22(1A):45-51. PubMed ID: 12017331
[TBL] [Abstract][Full Text] [Related]
16. Expression of TGF-beta isoforms, TGF-beta receptors, and SMAD molecules at different stages of human glioma.
Kjellman C; Olofsson SP; Hansson O; Von Schantz T; Lindvall M; Nilsson I; Salford LG; Sjögren HO; Widegren B
Int J Cancer; 2000 May; 89(3):251-8. PubMed ID: 10861501
[TBL] [Abstract][Full Text] [Related]
17. Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
Chen R; Cohen AL; Colman H
Curr Treat Options Oncol; 2016 Aug; 17(8):42. PubMed ID: 27334978
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Targeting of TGFβ Ligands in Glioblastoma Using Novel Antisense Oligonucleotides Reduces the Growth of Experimental Gliomas.
Papachristodoulou A; Silginer M; Weller M; Schneider H; Hasenbach K; Janicot M; Roth P
Clin Cancer Res; 2019 Dec; 25(23):7189-7201. PubMed ID: 31530630
[TBL] [Abstract][Full Text] [Related]
19. Toll-like receptor triggered dendritic cell maturation and IL-12 secretion are necessary to overcome T-cell inhibition by glioma-associated TGF-beta2.
Grauer O; Pöschl P; Lohmeier A; Adema GJ; Bogdahn U
J Neurooncol; 2007 Apr; 82(2):151-61. PubMed ID: 17106649
[TBL] [Abstract][Full Text] [Related]
20. IL-10 and TGF-β2 are overexpressed in tumor spheres cultured from human gliomas.
Qiu B; Zhang D; Wang C; Tao J; Tie X; Qiao Y; Xu K; Wang Y; Wu A
Mol Biol Rep; 2011 Jun; 38(5):3585-91. PubMed ID: 21088899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
